Skip to main content
. 2023 Jun 30;16:17562864231181177. doi: 10.1177/17562864231181177

Table 2.

Duration of eculizumab treatment and eculizumab treatment status (data for the safety analysis set, n = 71).

Patients who received eculizumab, n (%) (Safety analysis set, n = 71)
Overall eculizumab treatment duration, weeks
 Mean (SD) 44.6 (23.7)
 Median (range) 52.1 (0.1–104.4)
Total eculizumab cumulative dose, mg
 Mean (SD) 26,126 (13,393)
 Median (range) 31,114 (900–63,086)
Eculizumab treatment status, ongoing/discontinued, n (%)
 At week 26 62 (87.3)/9 (12.7)
 At year 1 40 (56.3)/1 (1.4)
 At year 2 4 (5.6)/2 (2.8)
 At interim analysis data cut-off (1 April 2022) 59 (83.1)/12 (16.9)
Reason for discontinuation
 Adverse event 3 (4.2)
 Death 0 (0.0)
 Lost to follow-up 0 (0.0)
 Physician decision 6 (8.5)
 Patient decision 5 (7.0)
 Relapse 0 (0.0)
 Symptomatic improvement 0 (0.0)
 Other 1 (1.4)
 Blank 0 (0.0)

SD, standard deviation.